Lifeward Q2 2024 revenue $6.7M (+400% YoY); net loss $0.50/shr, guidance reaffirmed

Lifeward Ltd.

2024-Q2 EPS reported -$1.23 revenue$11,990,000

Revenue of $6.7M, up from $1.3M in Q2 2023; ReWalk historical product revenue rose 131%.
Net loss of $4.3M ($0.50/shr) vs. $4.6M ($0.55/shr) a year ago; adjusted net loss $3.6M ($0.42/shr).
Record 20 ReWalk systems placed; Medicare claims from prior quarters beginning to be paid.
Cash $15.1M with no debt; FY 2024 revenue guidance maintained at $28M-$32M.
Launched NEO anti-gravity treadmill; FDA submission for 7th-gen ReWalk completed in June.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.